PolarityTE Receives Notice of Allowance for Chinese Patent

July 29, 2021

PolarityTE recently announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent Application No. 201580075326.3. The allowed claims relate to skin-regenerative compositions utilizing PolarityTE’s minimally polarized functional unit (MPFU) technology as well as methods of making a skin-regenerative composition utilizing the MPFU technology.

This most recent allowance further demonstrates the company’s steady march forward in acquiring patent rights on a global scale and brings the company’s total number of allowed and granted utility patents worldwide to 12 – 10 abroad and 2 in the United States. The company continues to pursue additional patent applications in the United States and abroad related to its regenerative technologies, including SkinTE®.

David Seaburg, Chief Executive Officer, commented, “In less than two years, PolarityTE has grown its worldwide patent portfolio from zero allowed or granted patents to 12.” Mr. Seaburg continued, “This most recent achievement further bolsters our intellectual property rights in our MPFU technology, aspects of which are central to SkinTE®.”

“This addition to PolarityTE’s growing list of patents recognizes the company’s exceptional work to utilize a patient’s own tissue, rather than a synthetic, to support the regenerative process,” said Kelvyn Cullimore, president and CEO of BioUtah.

PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.